Gastro-esophageal Reflux Disease (GERD) Completed Phase 4 Trials for Rabeprazole (DB01129)

Also known as: Reflux Disease, Gastro-Esophageal / Oesophageal Reflux / Gastroesophageal Refluxdisease / Gastrooesophageal reflux disease / Gastro-esophageal Reflux Disease / GERD / Esophageal Reflux / Gastroesophageal Reflux Disease (GERD) / Gastro Oesophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD (Gastroesophageal Reflux Disease) / Gastro-Oesophageal Reflux Disease / GERD - Gastro-Esophageal Reflux Disease / GERD Gastroesophageal Reflux Disease / Gastroesophageal Reflux Disease / Gastro Esophageal Reflux Disease / Gastrooesophageal reflux / Gastroesophageal reflux / Acid reflux (finding) / GORD / Gastro-esophageal reflux disease without esophagitis / Gastroesophageal reflux disease (disorder) / Esophageal reflux finding (finding)

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00354757CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor TestingDiagnostic
NCT00287391Sleep Disorders and Gastroesophageal Reflux Disease (GERD)Treatment
NCT03037606Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated TabletsTreatment
NCT00304421Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERDTreatment
NCT00251732Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)Treatment